Neumora Therapeutics (NMRA) Operating Expenses (2022 - 2026)

Neumora Therapeutics has reported Operating Expenses for 5 years, with the latest figure at $52.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 25.48% year-over-year to $52.9 million; the trailing twelve-month figure through Mar 2026 stood at $223.1 million (down 18.68% YoY), and the FY2025 full-year result was $241.2 million, down 8.47% from the prior year.
• Operating Expenses for Q1 2026 stood at $52.9 million, down from $58.5 million in the prior quarter.
• The five-year high for Operating Expenses was $114.0 million in Q4 2023, with the low at $30.6 million in Q3 2022.
• Average Operating Expenses over 5 years is $58.1 million, with a median of $57.7 million recorded in 2025.
• Year-over-year, Operating Expenses soared 271.13% in 2023 and sank 44.81% in 2024.
• Tracing NMRA's Operating Expenses over 5 years: stood at $30.7 million in 2022, then soared by 271.13% to $114.0 million in 2023, then slumped by 44.81% to $62.9 million in 2024, then dropped by 7.06% to $58.5 million in 2025, then fell by 9.6% to $52.9 million in 2026.
• The last three Operating Expenses figures came in at $52.9 million (Q1 2026), $58.5 million (Q4 2025), and $57.7 million (Q3 2025), per Business Quant data.

Peer Comparison